Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan
NEW YORK, Jan. 12, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company, announced today that it has prioritized its oncology development programs for 2016. Immune's oncology pipeline is comprised of three small molecules in mid to late stage clinical development and two novel technology platforms.
Dr. Daniel Teper, Immune's CEO commented: "We are focusing on disruptive technologies and targets that have the potential to change patient outcomes. In 2016 our goal is to generate data that will support partnerships and accelerate development thereby helping us bring life-changing therapies to cancer patients".
The company's Immuno-Oncology programs for 2016 include the following assets and data milestones:
Ceplene® in combination with low dose IL-2 is approved in 27 countries in Europe for remission maintenance and prevention of relapse in adults with Acute Myeloid Leukemia, an orphan indication with poor survival prognosis and no new therapy for many years. Ceplene® protects T Cell and Natural Killer (NK) cells against inactivation and apoptosis enabling IL-2 to eliminate leukemia cells and protect against relapse. Results of a post-marketing study conducted in Europe in a biomarker-defined sub-population are expected in 2016.
Azixa® and Crolibulin are two new vascular disruptive agents (VDAs) with additional anti-tumor activity demonstrated in preclinical studies. Both drugs have shown promising initial efficacy in phase I/II clinical trials in multiple solid tumors, including glioblastoma. Combination studies of VDAs with immune check-point inhibitors are underway in preclinical tumor models. These efforts will help provide the rationale for the design of a new phase II combination clinical study with a check point inhibitor.
Immune's two novel technology platforms, bispecific antibodies and immuno-nanoparticles (NanomAbs®), will be focused on immuno-oncology and applied to novel targets including immune check points. Pre-clinical validation with selected immune check point targets is planned in 2016.
About Immune Pharmaceuticals:
Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune's oncology pipeline includes, bispecific antibodies, nanotherapeutics (NanomAbs®), and several mid-to-late stage small molecules. Immune's non-core pipeline includes AmiKet®, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune's website at www.immunepharmaceuticals.com, the content of which is not a part of this press release.